Filtered By:
Specialty: Cardiology
Drug: Beta-Blockers

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 184 results found since Jan 2013.

Association of beta-blocker therapy at discharge with clinical outcomes in patients without heart failure or left ventricular systolic dysfunction after acute coronary syndrome: An updated systematic review and meta-analysis
CONCLUSIONS: In patients without heart failure or left ventricular systolic dysfunction after ACS in the contemporary PCI era, beta-blocker therapy may still be beneficial due to a potential reduced risk of all-cause death.PMID:36376209 | DOI:10.1016/j.acvd.2022.09.004
Source: Archives of Cardiovascular Diseases - November 14, 2022 Category: Cardiology Authors: Meng-Jin Hu Xiao-Ning Wang Jiang-Shan Tan Yue-Jin Yang Source Type: research

Betablockers reduce oxygen pulse increase and performance in heart failure patients with preserved ejection fraction
Beta blockers (BB) reduce chronotropic response and exercise capacity in heart failure with preserved ejection fraction (HFpEF). To analyze the influence of BB on exercise performance and O 2 pulse increase as a surrogate for stroke volume in HFpEF.
Source: International Journal of Cardiology - October 8, 2022 Category: Cardiology Authors: Wernhart Simon, Papathanasiou Maria, Amir Abbas Mahabadi, Rassaf Tienush, Luedike Peter Source Type: research

Higher mortality in acute coronary syndrome patients without standard modifiable risk factors: Results from a global meta-analysis of 1,285,722 patients
CONCLUSION: In this study level meta-analysis, SMuRF-less ACS patients demonstrate higher mortality compared with patients with at least one traditional atherosclerotic risk factor. Underuse of guideline-directed medical therapy amongst SMuRF-less patients is concerning. Unraveling novel risk factors amongst SMuRF-less individuals is the next important step.SUMMARY: Standard modifiable cardiovascular risk factors (SMuRF), comprising diabetes mellitus, hyperlipidemia, hypertension, and smoking, are often used for risk stratification in acute coronary syndrome (ACS). Recent studies showed an increasing proportion of SMuRF-le...
Source: Atherosclerosis - September 30, 2022 Category: Cardiology Authors: Gwyneth Kong Yip Han Chin Bryan Chong Rachel Sze Jen Goh Oliver Zi Hern Lim Cheng Han Ng Mark Muthiah Roger Foo Stephen T Vernon Poay Huan Loh Mark Y Chan Nicholas W S Chew Gemma A Figtree Source Type: research

Clinical impact of beta-blockers at discharge on long-term clinical outcomes in patients with non-reduced ejection fraction after acute myocardial infarction
CONCLUSIONS: The J-MINUET study revealed the clinical benefit of beta-blockers in AMI patients with non-REF after primary PCI.PMID:35995686 | DOI:10.1016/j.jjcc.2022.08.002
Source: Journal of Cardiology - August 22, 2022 Category: Cardiology Authors: Azusa Sakagami Tsunenari Soeda Yoshihiko Saito Koichi Nakao Yukio Ozaki Kazuo Kimura Junya Ako Teruo Noguchi Satoru Suwa Kazuteru Fujimoto Kazuoki Dai Takashi Morita Wataru Shimizu Atsushi Hirohata Yasuhiro Morita Teruo Inoue Atsunori Okamura Toshiaki Man Source Type: research

Nebivolol and incident cardiovascular events in hypertensive patients compared with nonvasodilatory beta blockers
Conclusion: The vasodilatory beta blocker nebivolol was associated with reduced incident cardiovascular events compared with nonvasodilatory beta blockers. Additional study of other beta blockers is necessary to determine if this is a vasodilatory beta blocker class effect or is specific to nebivolol. Graphical abstract: http://links.lww.com/HJH/B916
Source: Journal of Hypertension - May 1, 2022 Category: Cardiology Tags: ORIGINAL ARTICLES Source Type: research